$NVCT News

Roth Capital Maintains Buy on Nuvectis Pharma, Raises Price Target to $33

Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates

Reported Earlier, Nuvectis Pharma Prices $100M Public Offering Of 5M Common Shares At $20.00 Per Share

Nuvectis Pharma Commences Common Stock Offering; Terms Undisclosed

Haisco and Nuvectis sign licensing deal for two drugs

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending

Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)

HC Wainwright & Co. Maintains Buy on Nuvectis Pharma, Raises Price Target to $39

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript

Nuvectis Pharma Strikes License Agreement With Haisco Pharmaceutical Group For Exclusive Ex-China Rights To Two Compounds

HC Wainwright & Co. Maintains Buy on Nuvectis Pharma, Raises Price Target to $13

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Q1 EPS $(0.26) Beats $(0.32) Estimate

Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting